TuHURA Biosciences (HURA)
NASDAQ:HURA
Want to see HURA full AI Analyst Report?
Top Page
TuHURA Biosciences
(NASDAQ:HURA)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.50
▼(-14.38% Downside)
Action:Reiterated
Date:05/30/26
The score is primarily held back by weak financial performance (no revenue, sizable losses, and sustained negative free cash flow) despite low leverage. Technical indicators are neutral-to-mixed, and valuation is constrained by losses and no dividend. Corporate events modestly support the score via improved liquidity and runway from the new credit facility, tempered by its cost and restrictions.
Positive Factors
Low leverage and positive equity
A low-debt, positive-equity balance sheet gives TuHURA durable financial flexibility to fund clinical programs without large interest burdens. This reduces near-term default risk, supports non-dilutive options, and improves ability to negotiate partnerships or milestone financing over the next 2–6 months.
Negative Factors
No revenue and sustained net losses
TuHURA's development-stage profile with no commercial revenue means it cannot self-fund operations long-term. Persistent, widening net losses increase reliance on external financing, elevating dilution and financing risk and constraining reinvestment capacity across the planning horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and positive equity
A low-debt, positive-equity balance sheet gives TuHURA durable financial flexibility to fund clinical programs without large interest burdens. This reduces near-term default risk, supports non-dilutive options, and improves ability to negotiate partnerships or milestone financing over the next 2–6 months.
Read all positive factors
TuHURA Biosciences (HURA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$149.65M
Dividend YieldN/A
Average Volume (3M)215.15K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue GrowthN/A
EPS Growth94.79%
CountryUS
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding63,682,530
10 Day Avg. Volume212,396
30 Day Avg. Volume215,145
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.31
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.88K
Enterprise Value/Ebitda-4.57
Forecast
1Y Price Target
$8.00Price Target Upside173.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TuHURA Biosciences Business Overview & Revenue Model
Company Description
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL....
How the Company Makes Money
null...
TuHURA Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -55.00K | -60.00K | -60.00K |
| EBITDA | -29.36M | -17.43M | -8.27M | -14.74M | -22.62M |
| Net Income | -30.06M | -21.68M | -8.32M | -14.65M | -22.66M |
Balance Sheet | |||||
| Total Assets | 27.35M | 19.97M | 4.36M | 15.20M | 6.40M |
| Cash, Cash Equivalents and Short-Term Investments | 3.62M | 12.66M | 3.67M | 14.25M | 5.55M |
| Total Debt | 502.67K | 202.54K | 2.34M | 138.22K | 644.07K |
| Total Liabilities | 6.42M | 5.37M | 5.92M | 2.89M | 7.15M |
| Stockholders Equity | 20.93M | 14.59M | -1.56M | 12.30M | -747.82K |
Cash Flow | |||||
| Free Cash Flow | -27.71M | -14.79M | -12.03M | -7.54M | -6.57M |
| Operating Cash Flow | -27.63M | -14.73M | -11.95M | -7.51M | -6.56M |
| Investing Cash Flow | -1.34M | -6.05M | -1.30M | -36.28K | -3.28K |
| Financing Cash Flow | 19.93M | 29.77M | 2.66M | 16.25M | 7.04M |
TuHURA Biosciences Technical Analysis
Neutral
2.92
Price Trends
2.27
Negative
1.70
Positive
1.92
Positive
Market Momentum
0.02
Positive
46.21
Neutral
19.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HURA, the sentiment is Neutral. The current price of 2.92 is above the 20-day moving average (MA) of 2.40, above the 50-day MA of 2.27, and above the 200-day MA of 1.92, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 46.21 is Neutral, neither overbought nor oversold. The STOCH value of 19.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HURA.
TuHURA Biosciences Risk Analysis
TuHURA Biosciences disclosed 63 risk factors in its most recent earnings report. TuHURA Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TuHURA Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $106.50M | -5.38 | -72.68% | ― | ― | 64.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $149.65M | -4.38 | -153.99% | ― | ― | 94.79% | |
48 Neutral | $141.58M | 2.06 | -23.05% | ― | 24.46% | ― | |
48 Neutral | $99.77M | -2.22 | -196.72% | ― | ― | 74.83% | |
47 Neutral | $106.96M | -10.66 | -666.47% | ― | -100.00% | 46.40% | |
41 Neutral | $29.87M | -0.54 | -217.27% | ― | ― | -74.39% |
* Healthcare Sector Average
HURA
TuHURA Biosciences
2.26
-0.86
-27.56%
AGEN
Agenus
3.50
-0.63
-15.25%
INO
Inovio Pharmaceuticals
1.31
-0.79
-37.62%
SKYE
Skye Bioscience
0.78
-1.47
-65.40%
BMEA
Biomea Fusion
1.38
-0.17
-10.97%
CGTX
Cognition Therapeutics
1.18
0.86
268.75%
TuHURA Biosciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
TuHURA Biosciences Draws on New $50M Credit Facility
Positive
May 29, 2026
On April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC for a revolving credit facility of up to $50 million, maturing on April 21, 2031. On May 26, 2026, the company drew its first $1.7 million und...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
TuHURA Biosciences Extends Cash Runway and Advances Pipeline
Positive
May 15, 2026
On May 15, 2026, TuHURA Biosciences reported first-quarter 2026 results and a corporate update, highlighting a $50 million credit facility and royalty transaction announced in April that extends its projected cash runway into 2028 and provides fle...
Business Operations and StrategyPrivate Placements and Financing
TuHURA Biosciences Secures $50 Million Credit Facility
Positive
Apr 22, 2026
On April 21, 2026, TuHURA Biosciences, Inc. entered into a secured loan agreement with Parkview Holdings One LLC, an affiliate of its largest shareholder, establishing a revolving credit facility of up to $50 million maturing on April 21, 2031 at ...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresM&A Transactions
TuHURA Biosciences Approves 2025 Executive Compensation Adjustments
Positive
Apr 8, 2026
On April 2, 2026, TuHURA Biosciences’ board compensation committee approved 2025 performance bonuses and 5% cost-of-living salary increases for President and CEO Dr. James Bianco and CFO Dan Dearborn, underscoring the board’s continued...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.